Bruce Leicher Sells 728 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Bruce Leicher sold 728 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $15.90, for a total transaction of $11,575.20. Following the sale, the senior vice president now owns 171,194 shares in the company, valued at $2,721,984.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bruce Leicher also recently made the following trade(s):

  • On Monday, February 12th, Bruce Leicher sold 309 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $16.20, for a total transaction of $5,005.80.
  • On Wednesday, February 14th, Bruce Leicher sold 4,948 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $15.22, for a total transaction of $75,308.56.
  • On Thursday, February 8th, Bruce Leicher sold 1,861 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $16.00, for a total transaction of $29,776.00.

Shares of Momenta Pharmaceuticals, Inc. (MNTA) traded up $0.55 on Friday, reaching $16.90. The company had a trading volume of 1,762,200 shares, compared to its average volume of 955,981. The firm has a market capitalization of $1,248.93, a P/E ratio of -13.85 and a beta of 1.80. Momenta Pharmaceuticals, Inc. has a 52-week low of $11.85 and a 52-week high of $19.25.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.12. The firm had revenue of $64.60 million during the quarter, compared to the consensus estimate of $66.59 million. Momenta Pharmaceuticals had a negative return on equity of 23.62% and a negative net margin of 63.43%. The firm’s quarterly revenue was up 88.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.60 earnings per share. equities analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.32 EPS for the current fiscal year.

MNTA has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. BidaskClub lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Stifel Nicolaus restated a “hold” rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. ValuEngine upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. Finally, Cowen set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 1st. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $15.33.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. boosted its holdings in Momenta Pharmaceuticals by 12.0% in the third quarter. Principal Financial Group Inc. now owns 606,700 shares of the biotechnology company’s stock valued at $11,224,000 after purchasing an additional 65,014 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Momenta Pharmaceuticals in the third quarter valued at approximately $1,141,000. Candriam Luxembourg S.C.A. boosted its holdings in Momenta Pharmaceuticals by 15.0% in the third quarter. Candriam Luxembourg S.C.A. now owns 422,000 shares of the biotechnology company’s stock valued at $7,807,000 after purchasing an additional 55,000 shares in the last quarter. Fisher Asset Management LLC acquired a new position in Momenta Pharmaceuticals in the third quarter valued at approximately $1,823,000. Finally, Sectoral Asset Management Inc boosted its holdings in Momenta Pharmaceuticals by 24.4% in the third quarter. Sectoral Asset Management Inc now owns 372,499 shares of the biotechnology company’s stock valued at $6,891,000 after purchasing an additional 73,099 shares in the last quarter. 95.43% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Bruce Leicher Sells 728 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/23/bruce-leicher-sells-728-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply